CTI Announces Results from Sub-Set Analyses of Data from Phase 3 EXTEND Clinical Trial

News   Jul 15, 2013

 
CTI Announces Results from Sub-Set Analyses of Data from Phase 3 EXTEND Clinical Trial
 
 
 

RELATED ARTICLES

Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug Development

News

Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.

READ MORE

Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca

News

New programs added in respiratory and cardio-metabolic diseases.

READ MORE

Carcinogen Hazard From BBQ Smoke

News

Primary exposure to carcinogenic PAHs is through diet, however new research shows that skin was the second-highest exposure route, with barbecue smoke one of the main culprits.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE